TL;DR
- “Non-comedogenic” is one of the most overinterpreted claims in skincare — not meaningless, but far less rigorous and predictive than consumers assume
- No regulatory body formally defines or certifies the term, and substantiation methods vary considerably between manufacturers
- Most comedogenicity ingredient ratings come from animal model studies with real methodological limitations — formulation and concentration change how an ingredient actually behaves
- Individual response varies considerably — a product that clogs one person’s pores may be entirely fine for another
- The most reliable approach is introducing one new product at a time and monitoring your skin’s response over the following two to six weeks
“Non-comedogenic” is one of the most trusted claims in skincare. It is also one of the most overinterpreted from a regulatory standpoint — not meaningless, but considerably less rigorous and predictive than most people assume.
What the term means — and doesn’t
Neither the FDA nor most regulatory agencies formally define or certify “non-comedogenic.” There is no standardised test products must pass, no equivalent of an SPF test or drug approval process. Manufacturers are free to use the term, and the methods used to substantiate it vary considerably — some companies conduct genuine human-use studies, repeat-insult patch testing, or studies in acne-prone populations; others apply the label with minimal substantiation. The absence of a universal standard is the core problem, not an absence of any testing whatsoever.
Where the comedogenicity data comes from
Most comedogenicity ratings — the lists of ingredients scored 0–5 from non-comedogenic to highly comedogenic that circulate in skincare communities — derive substantially from animal model studies, primarily the rabbit ear model. This model has real limitations: rabbit ear skin differs significantly from human facial skin, concentrations used in testing were often higher than found in finished products, and the model does not account for formulation effects.
This last point matters enormously. The same ingredient at the same concentration can behave differently in different product vehicles. A comedogenicity rating assigned to pure isopropyl myristate does not reliably predict the behaviour of a finished moisturiser containing a small percentage of it alongside other ingredients that may buffer, dilute, or otherwise change its effect. Treating an isolated ingredient score as predictive of a finished product’s real-world behaviour is the core methodological gap.
What actually determines whether a product clogs your pores
Comedogenicity is not purely ingredient-driven. It is influenced by individual skin type, sebum production, hormonal state, genetics, climate, application technique, and overall formulation. An occlusive ingredient that clogs pores in someone with high sebum output may be entirely fine for someone with dry skin. Coconut oil is frequently cited as comedogenic, and it is one of the few ingredients where population-level concern is reasonably well-supported — but even here, individual response varies, and not everyone who uses it will break out.
It is also worth remembering that acne itself is not simply a matter of clogged pores. It involves follicular keratinisation, inflammation, the bacterium Cutibacterium acnes, and androgen signalling. Skincare products and their comedogenic potential are one factor among several — addressing product choice alone will not resolve acne that is substantially driven by hormonal or inflammatory factors.
What to actually do
The most reliable approach is introducing one new product at a time and monitoring how your skin responds over the following two to six weeks. This provides real data about your own skin’s response, rather than relying on a label that may have variable or minimal substantiation behind it. “Non-comedogenic” on a label is a reasonable signal — it often indicates a lighter formulation or the deliberate avoidance of known higher-risk ingredients — but it is a starting point for consideration, not a guarantee.
⚠️ Clinical note: “Non-comedogenic” is not a fraudulent or meaningless claim — it often does signal genuine formulation choices. The issue is that it is far less standardised and predictive than the confidence with which it is marketed would suggest. Persistent or severe acne is better addressed with a dermatologist than through product elimination alone, given how many factors beyond topical products contribute to the condition.
Sources
- Tran C, Lim AC, Burns T, et al. Comedogenicity in cosmeceuticals: A review of clinical relevance, regulatory gaps, and future directions. JAAD Reviews. 2025. doi:10.1016/j.jdin.2025.09.001
- Kligman AM, Mills OH. Acne cosmetica. Arch Dermatol. 1972;106(6):843–850.
- Fulton JE, Pay SR, Fulton JE. Comedogenicity of current therapeutic products, cosmetics, and ingredients in the rabbit ear. J Am Acad Dermatol. 1984;10(1):96–105.
- Kligman AM, Kwong T. An improved rabbit ear model for assessing comedogenic substances. Br J Dermatol. 1979;100(6):699–702.
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945–973. doi:10.1016/j.jaad.2015.12.037
- FDA. Cosmetics Labeling Claims. U.S. Food & Drug Administration. Available at: fda.gov/cosmetics/cosmetics-labeling/cosmetics-labeling-claims
- Decker A, Graber EM. Over-the-counter acne treatments: a review. J Clin Aesthet Dermatol. 2012;5(5):32–40. [Acne pathophysiology and role of C. acnes, follicular keratinisation, androgens, inflammation.]
